메뉴 건너뛰기




Volumn 133, Issue 5, 2010, Pages 1297-1299

Are we getting to grips with Alzheimer's disease at last

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN;

EID: 77951886964     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq099     Document Type: Note
Times cited : (2)

References (13)
  • 1
    • 11444267243 scopus 로고    scopus 로고
    • Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD
    • Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64: 94-101.
    • (2005) Neurology , vol.64 , pp. 94-101
    • Bayer, A.J.1    Bullock, R.2    Jones, R.W.3    Wilkinson, D.4    Paterson, K.R.5    Jenkins, L.6
  • 2
    • 1042265187 scopus 로고    scopus 로고
    • Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease
    • Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
    • (2004) Brain Pathol , vol.14 , pp. 11-20
    • Ferrer, I.1    Boada Rovira, M.2    Sanchez Guerra, M.L.3    Rey, M.J.4    Costa-Jussa, F.5
  • 3
    • 20944448555 scopus 로고    scopus 로고
    • Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
    • Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562
    • (2005) Neurology , vol.64 , pp. 1553-1562
    • Gilman, S.1    Koller, M.2    Black, R.S.3    Jenkins, L.4    Griffith, S.G.5    Fox, N.C.6
  • 5
    • 47149112621 scopus 로고    scopus 로고
    • Long term effect of Abeta42 immunization in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase i trial
    • Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long term effect of Abeta42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223
    • (2008) Lancet , vol.372 , pp. 216-223
    • Holmes, C.1    Boche, D.2    Wilkinson, D.3    Yadegarfar, G.4    Hopkins, V.5    Bayer, A.6
  • 6
    • 76849091134 scopus 로고    scopus 로고
    • Can Alzheimer disease be prevented by amyloid-beta immunotherapy?
    • Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010; 6: 108-119
    • (2010) Nat Rev Neurol , vol.6 , pp. 108-119
    • Lemere, C.A.1    Masliah, E.2
  • 7
    • 19944429065 scopus 로고    scopus 로고
    • Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
    • Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64: 129-131
    • (2005) Neurology , vol.64 , pp. 129-131
    • Masliah, E.1    Hansen, L.2    Adame, A.3    Crews, L.4    Bard, F.5    Lee, C.6
  • 9
    • 0037393454 scopus 로고    scopus 로고
    • Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report
    • Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452
    • (2003) Nat Med , vol.9 , pp. 448-452
    • Nicoll, J.A.1    Wilkinson, D.2    Holmes, C.3    Steart, P.4    Markham, H.5    Weller, R.O.6
  • 10
    • 33748767945 scopus 로고    scopus 로고
    • Amyloid-beta peptide remnants in AN-1792-immu-nized Alzheimer's disease patients: A biochemical analysis
    • Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al. Amyloid-beta peptide remnants in AN-1792-immu-nized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006; 169: 1048-1063
    • (2006) Am J Pathol , vol.169 , pp. 1048-1063
    • Patton, R.L.1    Kalback, W.M.2    Esh, C.L.3    Kokjohn, T.A.4    Van Vickle, G.D.5    Luehrs, D.C.6
  • 11
    • 77949300796 scopus 로고    scopus 로고
    • 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study
    • Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372
    • (2010) Lancet Neurol , vol.9 , pp. 363-372
    • Rinne, J.O.1    Brooks, D.J.2    Rossor, M.N.3    Fox, N.C.4    Bullock, R.5    Klunk, W.E.6
  • 12
    • 0033536163 scopus 로고    scopus 로고
    • Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
    • Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177
    • (1999) Nature , vol.400 , pp. 173-177
    • Schenk, D.1    Barbour, R.2    Dunn, W.3    Gordon, G.4    Grajeda, H.5    Guido, T.6
  • 13
    • 64549152492 scopus 로고    scopus 로고
    • Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders
    • Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6: 144-151
    • (2009) Curr Alzheimer Res , vol.6 , pp. 144-151
    • Vellas, B.1    Black, R.2    Thal, L.J.3    Fox, N.C.4    Daniels, M.5    McLennan, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.